NTLA
Price
$12.16
Change
-$0.97 (-7.39%)
Updated
Dec 18, 04:25 PM (EDT)
64 days until earnings call
RIGL
Price
$17.18
Change
-$1.27 (-6.88%)
Updated
Dec 18, 04:27 PM (EDT)
Ad is loading...

NTLA vs RIGL

Header iconNTLA vs RIGL Comparison
Open Charts NTLA vs RIGLBanner chart's image
Intellia Therapeutics
Price$12.16
Change-$0.97 (-7.39%)
Volume$4.7K
CapitalizationN/A
Rigel Pharmaceuticals
Price$17.18
Change-$1.27 (-6.88%)
Volume$700
CapitalizationN/A
NTLA vs RIGL Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. RIGL commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and RIGL is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (NTLA: $13.13 vs. RIGL: $18.45)
Brand notoriety: NTLA and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 104% vs. RIGL: 62%
Market capitalization -- NTLA: $1.34B vs. RIGL: $325M
NTLA [@Biotechnology] is valued at $1.34B. RIGL’s [@Biotechnology] market capitalization is $325M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileRIGL’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • RIGL’s FA Score: 0 green, 5 red.
According to our system of comparison, both NTLA and RIGL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while RIGL’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 4 bearish.
  • RIGL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both NTLA and RIGL are a good buy in the short-term.

Price Growth

NTLA (@Biotechnology) experienced а -10.80% price change this week, while RIGL (@Biotechnology) price change was -10.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.11%. For the same industry, the average monthly price growth was +0.93%, and the average quarterly price growth was +3.70%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

RIGL is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (-4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.34B) has a higher market cap than RIGL($325M). RIGL YTD gains are higher at: 27.241 vs. NTLA (-56.937). RIGL has higher annual earnings (EBITDA): 13.7M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. RIGL (61.1M). RIGL has less debt than NTLA: RIGL (60.2M) vs NTLA (102M). RIGL has higher revenues than NTLA: RIGL (157M) vs NTLA (43.1M).
NTLARIGLNTLA / RIGL
Capitalization1.34B325M411%
EBITDA-527.52M13.7M-3,851%
Gain YTD-56.93727.241-209%
P/E RatioN/A68.33-
Revenue43.1M157M27%
Total Cash658M61.1M1,077%
Total Debt102M60.2M169%
FUNDAMENTALS RATINGS
NTLA vs RIGL: Fundamental Ratings
NTLA
RIGL
OUTLOOK RATING
1..100
6555
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8939
P/E GROWTH RATING
1..100
10090
SEASONALITY SCORE
1..100
n/a33

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for RIGL (88). This means that NTLA’s stock grew somewhat faster than RIGL’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RIGL (100). This means that NTLA’s stock grew similarly to RIGL’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as RIGL (100). This means that NTLA’s stock grew similarly to RIGL’s over the last 12 months.

RIGL's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for NTLA (89). This means that RIGL’s stock grew somewhat faster than NTLA’s over the last 12 months.

RIGL's P/E Growth Rating (90) in the Biotechnology industry is in the same range as NTLA (100). This means that RIGL’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLARIGL
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 17 days ago
78%
Bullish Trend 22 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GFVUX16.09N/A
N/A
Goldman Sachs Focused Value R6
JACRX13.66-0.05
-0.36%
Easterly Global Real Estate C
ATWCX22.61-0.14
-0.62%
AB Tax-Managed Wealth Apprec Strat C
SINAX44.58-0.38
-0.85%
ClearBridge Large Cap Value A
MGRQX37.78-2.08
-5.22%
MFS International Growth R2

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.87%
VCYT - NTLA
69%
Closely correlated
-2.52%
EDIT - NTLA
68%
Closely correlated
+2.70%
BEAM - NTLA
66%
Loosely correlated
-1.21%
CRSP - NTLA
62%
Loosely correlated
+0.88%
PRME - NTLA
59%
Loosely correlated
-3.00%
More

RIGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, RIGL has been loosely correlated with RCUS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if RIGL jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RIGL
1D Price
Change %
RIGL100%
-3.61%
RCUS - RIGL
38%
Loosely correlated
-2.60%
NTLA - RIGL
37%
Loosely correlated
-1.87%
AGIO - RIGL
37%
Loosely correlated
-1.71%
WVE - RIGL
36%
Loosely correlated
+7.43%
ALT - RIGL
35%
Loosely correlated
-6.67%
More